Abstract 3478: PI3K suppression by the mTOR inhibitor ridaforolimus and the AKT inhibitor MK-2206 is associated with enhanced anti-tumor activity and hyperglycemia in preclinical models
Marlene C. Artime(Merck & Co., Inc., Rahway, NJ, USA (United States)), Brian B. Haines(Boston Biomedical Research Institute), James Watters(Sanofi (France)), Alessandra Di Bacco(Millennium Engineering and Integration (United States)), C.M. Chavez-Eng(United States Military Academy), Edwin Clark(Merck & Co., Inc., Rahway, NJ, USA (United States)), Christopher Winter(Dana-Farber Cancer Institute), Ray Lee(Gwynedd Mercy University), Mélissa Chénard(Merck & Co., Inc., Rahway, NJ, USA (United States)), Punam Sandhu(United States Military Academy), Gail Gitzlaff(United States Military Academy), Nagaraja Muniappa(United States Military Academy), Theresa Zhang(Human Genome Sciences (United States)), Scot Ebbinghaus(Merck & Co., Inc., Rahway, NJ, USA (United States)), Samuel C. Blackman, Diana Gargano(Merck & Co., Inc., Rahway, NJ, USA (United States))
Cited by 1
Related Papers
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k